Compass Diversified Holdings, a traded fund in New York Stock Exchange, seeks investment opportunities in small and middle-market companies located in North America with an enterprise value of USD ...

June 8 : Data analytics software firm Databricks has discussed raising funds in a round that could begin next month and value it at between $165 billion and $175 billion, The Information reported on ...

Some of the best navigators on Earth don’t have GPS. They don’t even have much of a brain. One of them is a beetle. A dung beetle. On the darkest, moonless nights, it can roll a ball of dung in an ...

Both companies face lawsuits and antitrust inquiries as they attempt to control the experience of home buying. By Elizabeth A. Harris Over the past year, Zillow, the country’s largest real estate ...

Pune: Bakliwal Tutorials (BT) has once again delivered an impressive performance in the JEE Advanced 2026 examination, reinforcing its position as one of Pune’s leading engineering entrance coaching ...

Real-estate brokerage Compass COMP3.17%increase; up pointing triangle, which became an industry giant after acquiring rival Anywhere Real Estate earlier this year, is under investigation by the ...

PROMOTING AMERICAN AI INNOVATION AND SECURITY: Today, President Donald J. Trump signed an Executive Order to advance American artificial intelligence (AI) innovation to strengthen America’s ...

Section 1. Purpose. The United States continues to lead the world in Artificial Intelligence (AI) because of the enormous talent and innovation of our AI industry, and because we refuse to stifle this ...

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with ...

Greetings. Welcome to Compass Therapeutics Top-line Secondary Endpoints Call. [Operator Instructions] Please note, this conference is being recorded. At this time, I'll turn the conference over to ...

Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an overall survival (OS) endpoint in a phase 2/3 study. The Boston-based ...